These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 22342281

  • 1. Preparation of cryoprecipitate from riboflavin and UV light-treated plasma.
    Ettinger A, Miklauz MM, Bihm DJ, Maldonado-Codina G, Goodrich RP.
    Transfus Apher Sci; 2012 Apr; 46(2):153-8. PubMed ID: 22342281
    [Abstract] [Full Text] [Related]

  • 2. Quality of proteins in riboflavin and UV light-treated FFP during 1 year of storage at -18°C.
    Ettinger A, Miklauz MM, Hendrix BK, Bihm DJ, Maldonado-Codina G, Goodrich RP.
    Transfus Apher Sci; 2012 Feb; 46(1):15-8. PubMed ID: 22115607
    [Abstract] [Full Text] [Related]

  • 3. Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma.
    Smith J, Rock G.
    Transfusion; 2010 Apr; 50(4):926-31. PubMed ID: 20051060
    [Abstract] [Full Text] [Related]

  • 4. Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at -30 degrees C.
    Bihm DJ, Ettinger A, Buytaert-Hoefen KA, Hendrix BK, Maldonado-Codina G, Rock G, Giclas PC, Goodrich RP.
    Vox Sang; 2010 Feb; 98(2):108-15. PubMed ID: 19719460
    [Abstract] [Full Text] [Related]

  • 5. Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins.
    Hornsey VS, Drummond O, Morrison A, McMillan L, MacGregor IR, Prowse CV.
    Transfusion; 2009 Oct; 49(10):2167-72. PubMed ID: 19555414
    [Abstract] [Full Text] [Related]

  • 6. Cryoprecipitate prepared from plasma treated with methylene blue plus light: increasing the fibrinogen concentration.
    Hornsey VS, Young DA, Docherty A, Hughes W, Prowse CV.
    Transfus Med; 2004 Oct; 14(5):369-74. PubMed ID: 15500456
    [Abstract] [Full Text] [Related]

  • 7. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
    Burnouf T, Goubran HA, Radosevich M, Sayed MA, Gorgy G, El-Ekiaby M.
    Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
    [Abstract] [Full Text] [Related]

  • 8. Protein stability of previously frozen plasma, riboflavin and UV light-treated, refrozen and stored for up to 2 years at -30 °C.
    Ettinger A, Miklauz MM, Hendrix BK, Bihm DJ, Maldonado-Codina G, Goodrich RP.
    Transfus Apher Sci; 2011 Feb; 44(1):25-31. PubMed ID: 21251884
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Quantitative and qualitative analysis of coagulation factors in cryoprecipitate prepared from fresh-frozen plasma inactivated with amotosalen and ultraviolet A light.
    Cid J, Caballo C, Pino M, Galan AM, Martínez N, Escolar G, Diaz-Ricart M.
    Transfusion; 2013 Mar; 53(3):600-5. PubMed ID: 22738354
    [Abstract] [Full Text] [Related]

  • 11. Plasma constituent integrity in pre-storage vs. post-storage riboflavin and UV-light treatment--a comparative study.
    Balint B, Jovicic-Gojkov D, Todorovic-Balint M, Subota V, Pavlovic M, Goodrich R.
    Transfus Apher Sci; 2013 Dec; 49(3):434-9. PubMed ID: 23820430
    [Abstract] [Full Text] [Related]

  • 12. Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma.
    Caudill JS, Nichols WL, Plumhoff EA, Schulte SL, Winters JL, Gastineau DA, Rodriguez V.
    Transfusion; 2009 Apr; 49(4):765-70. PubMed ID: 19192257
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Riboflavin and ultraviolet light for pathogen reduction of murine cytomegalovirus in blood products.
    Keil SD, Saakadze N, Bowen R, Newman JL, Karatela S, Gordy P, Marschner S, Roback J, Hillyer CD.
    Transfusion; 2015 Apr; 55(4):858-63. PubMed ID: 25438832
    [Abstract] [Full Text] [Related]

  • 15. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light.
    Cardo LJ, Rentas FJ, Ketchum L, Salata J, Harman R, Melvin W, Weina PJ, Mendez J, Reddy H, Goodrich R.
    Vox Sang; 2006 Feb; 90(2):85-91. PubMed ID: 16430665
    [Abstract] [Full Text] [Related]

  • 16. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light.
    Cardo LJ, Salata J, Mendez J, Reddy H, Goodrich R.
    Transfus Apher Sci; 2007 Oct; 37(2):131-7. PubMed ID: 17950672
    [Abstract] [Full Text] [Related]

  • 17. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction.
    Picker SM, Oustianskaia L, Schneider V, Gathof BS.
    Vox Sang; 2009 Jul; 97(1):26-33. PubMed ID: 19302416
    [Abstract] [Full Text] [Related]

  • 18. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns.
    Goodrich RP, Gilmour D, Hovenga N, Keil SD.
    Transfusion; 2009 Jun; 49(6):1205-16. PubMed ID: 19320867
    [Abstract] [Full Text] [Related]

  • 19. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
    Palmer DS, Ganz PR, Perkins H, Rosborough D, Rock G.
    Thromb Haemost; 1990 Jun 28; 63(3):392-402. PubMed ID: 2119525
    [Abstract] [Full Text] [Related]

  • 20. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
    Perez-Pujol S, Tonda R, Lozano M, Fuste B, Lopez-Vilchez I, Galan AM, Li J, Goodrich R, Escolar G.
    Transfusion; 2005 Jun 28; 45(6):911-9. PubMed ID: 15934989
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.